[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@MarketPulse360 Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1517444811296587777.png) @MarketPulse360 Market Pulse 360°

Market Pulse 360° posts on X about $iinn, nasdaq, india, dr reddys the most. They currently have XX followers and XX posts still getting attention that total X engagements in the last XX hours.

### Engagements: X [#](/creator/twitter::1517444811296587777/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1517444811296587777/c:line/m:interactions.svg)

- X Week XXX +1,237%
- X Month XXX +112%
- X Months XXXXX +637%
- X Year XXXXXX +421%

### Mentions: X [#](/creator/twitter::1517444811296587777/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1517444811296587777/c:line/m:posts_active.svg)

- X Week X +300%
- X Month XX +240%
- X Months XX +92%
- X Year XX +152%

### Followers: XX [#](/creator/twitter::1517444811296587777/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1517444811296587777/c:line/m:followers.svg)

- X Week XX no change
- X Month XX +11%
- X Months XX +35%

### CreatorRank: undefined [#](/creator/twitter::1517444811296587777/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1517444811296587777/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1517444811296587777/influence)
---

**Social category influence**
[exchanges](/list/exchanges)  XXXX% [finance](/list/finance)  XXXX% [countries](/list/countries)  XXXX% [stocks](/list/stocks)  XXXX%

**Social topic influence**
[$iinn](/topic/$iinn) 8.33%, [nasdaq](/topic/nasdaq) 8.33%, [india](/topic/india) 8.33%, [dr reddys](/topic/dr-reddys) 8.33%, [$rdy](/topic/$rdy) 8.33%, [sanofi](/topic/sanofi) 8.33%, [$phge](/topic/$phge) 8.33%, [weight loss](/topic/weight-loss) 8.33%, [$ptnt](/topic/$ptnt) XXXX%

**Top assets mentioned**
[Dr. Reddy's Laboratories Limited American Depositary Shares (RDY)](/topic/$rdy) [Sanofi (SNY)](/topic/sanofi)
### Top Social Posts [#](/creator/twitter::1517444811296587777/posts)
---
Top posts by engagements in the last XX hours

"Inspira Technologies Regains Nasdaq Compliance: Minimum Bid Price Achieved $IINN ➡ Inspira Technologies received notification from Nasdaq confirming compliance with the minimum bid price requirement. ➡ The company's common shares maintained a closing bid price at or above $XXXX per share for XX consecutive business days. ➡ According to the announcement Inspira's CEO Dagi Ben-Noon views this compliance as a reflection of market confidence in the company's strategic direction. ➡ Inspira is focusing on global distribution and execution leveraging achievements like a large commercial order and"  
![@MarketPulse360 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1517444811296587777.png) [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1946192967980462470) 2025-07-18 12:58:56 UTC XX followers, XXX engagements


"Dr. Reddy's Launches Sanofi's Beyfortus in India for RSV Prevention #DRREDDY $RDY ➡ Dr. Reddys Laboratories has launched Beyfortus (nirsevimab) in India a preventive treatment for Respiratory Syncytial Virus (RSV) in infants following an expanded partnership with Sanofi. ➡ RSV is a significant yet underreported health crisis in India causing many respiratory infections in infants with experts reporting over 2000 child deaths in 2024 from Kolkata Bengaluru and Mumbai alone. ➡ According to the Article Beyfortus launch aligns with Dr. Reddy's dual-track growth strategy strengthening its core"  
![@MarketPulse360 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1517444811296587777.png) [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1945970502436020389) 2025-07-17 22:14:56 UTC XX followers, XXX engagements


"BiomX Initiates Phase 2b Trial for BX004 a Potential Game-Changer $PHGE ➡ BiomX has dosed the first patient in its Phase 2b trial for BX004 targeting Pseudomonas aeruginosa in cystic fibrosis patients. ➡ The company's phage therapy approach aims to combat antibiotic-resistant infections with promising Phase 1b/2a results showing complete bacterial clearance in some patients. One patient according to the article had been infected for XX years before achieving complete clearance. ➡ BX004 has received FDA Fast Track and Orphan Drug designations potentially accelerating its path to market;"  
![@MarketPulse360 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1517444811296587777.png) [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1944761171925496244) 2025-07-14 14:09:29 UTC XX followers, XXX engagements


"$PTNT Oral MC4R Agonist PL7737 Shows Positive Preclinical Data in Obesity Model ➡ According to the announcement Palatin Technologies' oral MC4R agonist PL7737 demonstrated significant weight loss in preclinical studies using a diet-induced obese rat model. ➡ Monotherapy with oral PL7737 resulted in rapid weight loss with a high dose achieving XX% weight loss after just X days of treatment based on the announcement. ➡ The combination of oral PL7737 and tirzepatide showed additive effects leading to a XX% weight loss with the high dose combination according to the announcement. ➡ Palatin is"  
![@MarketPulse360 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1517444811296587777.png) [@MarketPulse360](/creator/x/MarketPulse360) on [X](/post/tweet/1945091851066695844) 2025-07-15 12:03:30 UTC XX followers, XX engagements